Modulation of hypothalamic AMPK phosphorylation by olanzapine controls energy balance and body weight

[Background]: Second-generation antipsychotics (SGAs) are a mainstay therapy for schizophrenia. SGA-treated patients present higher risk for weight gain, dyslipidemia and hyperglycemia. Herein, we evaluated the effects of olanzapine (OLA), widely prescribed SGA, in mice focusing on changes in body w...

Descripción completa

Detalles Bibliográficos
Autores: Ferreira, Vítor, Folgueira, Cintia, Guillén Gómez, María José, Zubiaur, Pablo, Navares-Gómez, Marcos, Sarsenbayeva, Assel, López-Larrubia, Pilar, Eriksson, Jan W., Pereira, Maria J., Abad-Santos, Francisco, Sabio, Guadalupe, Rada, Patricia, Valverde, Ángela M.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/295479
Acceso en línea:http://hdl.handle.net/10261/295479
Access Level:acceso abierto
Palabra clave:Olanzapine
Hypothalamus
Adipose tissue
Inter-organ crosstalk
Thermogenesis
Sympathetic innervation
Descripción
Sumario:[Background]: Second-generation antipsychotics (SGAs) are a mainstay therapy for schizophrenia. SGA-treated patients present higher risk for weight gain, dyslipidemia and hyperglycemia. Herein, we evaluated the effects of olanzapine (OLA), widely prescribed SGA, in mice focusing on changes in body weight and energy balance. We further explored OLA effects in protein tyrosine phosphatase-1B deficient (PTP1B-KO) mice, a preclinical model of leptin hypersensitivity protected against obesity.

Similares en LA Referencia